Abstract LB181: First disclosure of XRD-0394, a novel dual ATM/DNA-PK inhibitor, that potently radiosensitizes and potentiates PARP and topoisomerase inhibitors
Tona M. Gilmer(GlaxoSmithKline (United States)), Michael B. Kastan(Duke University), Yaode Wang(Beijing Solar Energy Research Institute), Amy E. Stewart(Duke University), Kris C. Wood(Duke University), Michael F. Gensheimer(Stanford University), Paul B. Romesser(Howard Hughes Medical Institute), Jonathan T. Yang(New York University), Katherine Deland(Duke University), David G. Kirsch(Princess Margaret Cancer Centre), Kathleen A. Ashcraft(Duke University), Jianmin Fu(Beijing Solar Energy Research Institute), Deborah A. Smith, Steven H. Lin(The University of Texas MD Anderson Cancer Center), Chun-Hsiang Lai(Duke University), Christopher T. Chen(Cancer Institute (WIA)), Kexiao Guo(Duke University)
Cited by 4
Related Papers
Restoration of p53 function leads to tumour regression in vivo
|Nature|2007|1.8k
Oncogenically active MYD88 mutations in human lymphoma
|Nature|2010|1.5k
The complexity of p53 modulation: emerging patterns from divergent signals
|Genes & Development|1998|1.3k
DNA damage induces phosphorylation of the amino terminus of p53
|Genes & Development|1997|824